Effectiveness of denosumab, teriparatide and romosozumab for glucocorticoid-induced osteoporosis: a propensity score-matched cohort study
BTM levels reflected expected pharmacological actions of each drug. ROMO showed greater LS BMD gains than DMAb, while TPTD demonstrated a similar response, whereas DMAb may provide earlier benefits at cortical-rich sites. These findings underscore the importance of site-specific, individualized treatment strategies for GIOP.
Authors
- Yuki Etani (ORCID: https://orcid.org/0000-0001-5741-5969)
- Tomonori Kobayakawa
- Y Hirano
- Seiji Okada (ORCID: https://orcid.org/0000-0002-5107-8209)
- Kumiko Shimoyama
- Yasuhide Kanayama (ORCID: https://orcid.org/0000-0002-2409-1619)
- Toshitaka Yukishima (ORCID: https://orcid.org/0000-0003-2265-6724)
- Rui Niimi
- Kosuke Ebina
- Ken Nakata
- Takaaki Noguchi
Institutions
- Hamamatsu University (JP)
- Osaka University of Health and Sport Sciences (JP)
- Niimi College (JP)
- Hamamatsu University School of Medicine (JP)
- Toyota Kosei Hospital (JP)
- Toyohashi Municipal Hospital (JP)
- Shizuoka Institute of Science and Technology (JP)
- The University of Osaka (JP)
Publication Details
- Journal
- Lara D. Veeken
- Published
- 2026-02-05
- DOI
- https://doi.org/10.1093/rheumatology/keag082
- Primary Topic
- Bone health and osteoporosis research
- Type
- article
- Field-Weighted Citation Impact
- 0.00